Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Epsilon Molecular Engineering

    Menu

    Epsilon Molecular Engineering

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Epsilon Molecular Engineering

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering

              Details:

              With these investments, Epsilon Molecular Engineering plans to further promote its next-generation biotechnology-based drug discovery research and development focusing on heavy chain single domain antibodies, VHH antibody.

              Lead Product(s): VHH antibody

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital

              Deal Size: $5.4 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY